// App-Quantinova.ai

LB-350 : Robust correlation of Galectin-9 expression with immunological tumor features and outcome in multiple tumor types establishes it as both a novel therapeutic target and a biomarker

Researchers

Presenter

  • Aleksandra Filipovic

Principal Investigators

  • Shohei Koide

  • Linxiao Chen

  • David T. Ting

  • Mohammad Ilyas

  • Wakkas Fadhil

  • Emad Rakha

  • Andrew Green

Medical Centers

  • PureTech Health, Boston, MA

  • Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom

  • Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute and Department of Histopathology, Nottingham City Hospital, Nottingham, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Advanced biliary tract carcinoma

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Receptor 7

  • Cluster of Differentiation 1a

  • Cluster of Differentiation 24

  • Cluster of Differentiation 56

  • Cluster of differentiation 8A

  • Forkhead Box P3

  • Interferon-gamma

  • Interleukin 17A

Drug/Treatment

  • galectin-9

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved